Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Efficacy and safety of amphotericin B and azoles in the treatment of invasive fungal disease
The medical records, demographic characteristics and clinical data of patients with invasive fungal disease treated with amphotericin B or azoles were collected through the electronic medical record system of Sichuan Provincial People's Hospital from 2021 to 2024. To evaluate the efficacy and safety of these two types of drugs.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment with polyene antifungal drugs | The dosage and course of Amphotericin B or Amphotericin B cholesteryl sulphate complex were determined by clinicians, and this study was registered according to clinical practice | ||
| Treatment with azole antifungal drugs | The dosage and course of triazoles or imidazole antifungal drugs were determined by clinicians, and this study was registered according to clinical practice |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Clinical success rate | Clinical success incudes cure or symptom improvement,which means patients are alive, IFD-related symptoms and signs, radiographic abnormalities improve or disappear completely, and microbiological evidence suggests fungal clearance. The proportion of patients with cured or improved symptoms in the total population was analyzed. | The end of treatment, up to 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Safety of amphotericin B and azoles | Safety evaluation was mainly based on the incidence of adverse events / adverse reactions in the two groups of patients. | During the treatment (1-14 days); the end of treatment (Day 14);Day 28 after the start of treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for ≥ 7 days.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| lingai Pan, PhD | Contact | 17708130236 | panlingai2004@163.com |
| Name | Affiliation | Role |
|---|---|---|
| lingai PP Pan, PhD | Sichuan Provincial People's Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sichuan Provincial People's Hospital | Recruiting | Chengdu | Sichuan | 610072 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000072742 | Invasive Fungal Infections |
| ID | Term |
|---|---|
| D009181 | Mycoses |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided